Moderna Says It Could Have an RSV Vaccine as Soon as Next Year

By Rowan Walrath • Published November 3, 2022 • Updated on November 3, 2022 at 10:58 am

Moderna Inc. says its vaccine for respiratory syncytial virus, better known as RSV, could be ready for commercialization as soon as next year.

The Cambridge drugmaker is currently running a Phase 3 trial of its mRNA-based RSV vaccine. Data is expected sometime this winter; if it meets expectations, then Moderna could launch it before the fall 2023 sick season, executives said on the company's third-quarter earnings call Thursday morning.

WATCH ANYTIME FOR FREE